Melatonin Use in Psychiatry-Quo Vadis?

Ahmed Naguy 1, Bibi Al-Amiri 2 3 4, Tarek Shoukry 5 6

Affiliations

01 September 2020

-

doi: 10.1097/MJT.0000000000000833

Abstract

Melatonin use in clinical psychiatry is currently rife, and the trend of utilization is on the rise. Efficacy coupled with safety and lack of abuse potential render melatonin an attractive therapeutic option. Data from neuroscience accrue speaking to the idea of a pluripotent molecule beyond a mere sleeping aid. Here, authors would shed some light on melatonin use in psychiatry while examining the extant evidence.

Similar articles

[Melatonin--a new fashionable drug or substance with definite effect?].

Waldhauser F.Wien Klin Wochenschr. 1997 Oct 3;109(18):705-6.PMID: 9441512 German. No abstract available.

Melatonin and its agonists, circadian rhythms and psychiatry.

Verster GC.Afr J Psychiatry (Johannesbg). 2009 Feb;12(1):42-6. doi: 10.4314/ajpsy.v12i1.30277.PMID: 19517046 Review.

Pretreatment circadian period in free-running blind people may predict the phase angle of entrainment to melatonin.

Lewy AJ, Hasler BP, Emens JS, Sack RL.Neurosci Lett. 2001 Nov 9;313(3):158-60. doi: 10.1016/s0304-3940(01)02261-3.PMID: 11682151 Clinical Trial.

[The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson's disease].

Datieva VK, Rosinskaia AV, Levin OS.Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7 Pt 2):77-81.PMID: 23994935 Clinical Trial. Russian.

Role of melatonin in the regulation of human circadian rhythms and sleep.

Cajochen C, Kräuchi K, Wirz-Justice A.J Neuroendocrinol. 2003 Apr;15(4):432-7. doi: 10.1046/j.1365-2826.2003.00989.x.PMID: 12622846 Review.

Cited by

Therapeutic use of melatonin in schizophrenia-more than meets the eye!

Naguy A.World J Psychiatry. 2022 Mar 19;12(3):533-535. doi: 10.5498/wjp.v12.i3.533. eCollection 2022 Mar 19.PMID: 35433328 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Pacchierotti C, Iapichino S, Bossini L, et al. Melatonin in psychiatric disorders: a review of melatonin involvement in psychiatry. Front Neuroendocrinol. 2001;22:18–32.
  2.  
    1. Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15:434.
  3.  
    1. Middleton B, Arendt J, Stone BM. Complex effects of melatonin on human circadian rhythms in constant dim light. J Biol Rhythms. 1997;12:467–477.
  4.  
    1. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8:e63773.
  5.  
    1. Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep. 1997;20:124–131.
  6.  
    1. Sanchez-Barcelo EJ, Mediavilla MD, Reiter RJ. Clinical uses of melatonin in pediatrics. Int J Pediatr. 2011;2011:892624.
  7.  
    1. Naguy A. Successful use of sertindole for severe behavioural dyscontrol in a pediatric case of syndromic autism spectrum disorder. J Child Adolesc Psychopharmacol. 2017;27:471–472.
  8.  
    1. Melke J, Goubran Botros H, Chaste P, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. 2008;13:90–98.
  9.  
    1. Rossignol D, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53:783–792.
  10.  
    1. Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord. 2011;41:175–184.
  11.  
    1. Malow BA, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012;42:1729–1737.
  12.  
    1. Naguy A, Al-Tajali A. Agomelatine addressing behavioural facets in autism. J Psychiatry. 2015;18:283.
  13.  
    1. Naguy A. Psychopharmacotherapy of ADHD complex presentations. Pediatr Neurol. 2017. In Press.
  14.  
    1. Weiss MD, Wasdell MB, Bomben MM, et al. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry. 2006;45:512–519.
  15.  
    1. Van der Heijden KB, Smits MG, Van Someren EJ, et al. Effect of melatonin on sleep, behaviour, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46:233–241.
  16.  
    1. Niederhofer H, Staffen W, Mair A, et al. Brief report: melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Dev Disord. 2003;33:469–472.
  17.  
    1. Gupta M, Gupta YK, Aneja AS, et al. Effects of add-on melatonin on sleep in epileptic children on carbamazepine monotherapy: a randomized placebo-controlled trial. Sleep Biol Rhythms. 2004;2:215–219.
  18.  
    1. Jain S, Besag FM. Does Melatonin affect epileptic seizures? Drug Saf. 2013;36:207–215.
  19.  
    1. Wongprayoon P, Govitrapong P. Melatonin as a mitochondrial protector in neurodegenerative diseases. Cell Mol Life Sci. 2017;74:3999–4014.
  20.  
    1. Naguy A, Francis K. Melatonin: a new game-changer in juvenile bipolar disorders? Psychiatr Res. 2016. In Press.
  21.  
    1. Bersani G, Garavini A. Melatonin add-on in manic patients with treatment resistent insomnia. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:185–191.
  22.  
    1. Robertson JM, Tanguay PE. Case study: the use of melatonin in a boy with Refractory bipolar disorder. J Am Acad Child Adolesc Psychiatry. 1997;36:822–825.
  23.  
    1. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27: 113–119.
  24.  
    1. Morera-Fumero AL, Abreu-gonzalez P. Role of melatonin in schizophrenia. Int J Mol Sci. 2013;14:9037–9050.
  25.  
    1. Nasrallah H. Are you neuroprotecting your patients? 10 Adjunctive therapies to consider. Curr Psychiatry. 2016;15:12–14.
  26.  
    1. He H, Dong W, Huang F. Anti-amyloidogenic and anti-apoptotic role of melatonin in alzheimer disease. Curr Neuropharmacol. 2010;8:211–217.
  27.  
    1. Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr Neuropharmacol. 2010;8:218–227.
  28.  
    1. Chen S, Shi L, Liang F, et al. Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials. Mol Neurobiol. 2016;53:4046–4053.
  29.  
    1. Hatta K, Kishi Y, Wada K, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71:397–403.
  30.  
    1. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58:1049–1052.
  31.  
    1. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guidelines: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–469.
  32.  
    1. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. The role of melatonin in acute myocardial infarction. Front Biosci (landmark Ed). 2012;17:2433–2441.
  33.  
    1. McMullan C, Schernhammer E, Rimm E, et al. Melatonin secretion and the incidence of type 2 diabetes. JAMA. 2013;309:1388–1396.
  34.  
    1. Romo-Nava F, Gonzalez D, Fresan-Orellana A, et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014;16:410–421.
  35.  
    1. Goyal A, Terry PD, Superak HM, et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetol Met Synd. 2014;6:124.
  36.  
    1. Mostafavi A, Solhi M, Mohammadi MR, et al. Melatonin decreases olanzapine induced metabolic side effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta Med Iran. 2014;52:734–739.
  37.  
    1. Modabberina A, Heidari P, Soleimani R, et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res. 2014;53:133–140.

Page Navigation